Molly Gibson
About Molly Gibson
Molly Gibson is the co-founder and Chief Innovation Officer at Generate:Biomedicines and an origination partner at Flagship Pioneering, specializing in the intersection of biology and machine learning.
Molly Gibson Co-Founder and Chief Innovation Officer
Molly Gibson is the Co-Founder and Chief Innovation Officer of Generate:Biomedicines, a company under the Flagship Pioneering umbrella. In her role, she oversees corporate strategy, platform and data strategy, and leads an innovation group known as G:Labs. This team is dedicated to exploring novel applications of The Generate Platform. Her position requires a deep understanding of both corporate dynamics and advanced biotechnological innovation.
Molly Gibson at Flagship Pioneering
Molly Gibson also serves as an origination partner at Flagship Pioneering, where she is part of a venture-creation team. At Flagship Pioneering, she works at the intersection of biology and machine learning to found and grow innovative companies. Her role in this venture-creation team highlights her ability to conceptualize and implement groundbreaking biotech enterprises.
Contributions to Tessera Therapeutics and Cobalt Biomedicines
Molly Gibson has been instrumental in the launch and growth of Tessera Therapeutics and Cobalt Biomedicines. Cobalt Biomedicines later merged into Sana Biotechnology. These companies signify key milestones in her career, emphasizing her role in developing advanced therapies and biotechnological solutions.
Molly Gibson Achievements and Recognitions
Molly Gibson has received notable accolades in her field. In 2020, she was honored in Endpoints News' 20 under 40 list in biopharma. The following year, she featured in Business Insiders’ list of 12 young serial entrepreneurs building the next generation of biotech startups. These recognitions underscore her impact and influence in the biopharma industry.
Molly Gibson Education and Research
Molly Gibson earned her PhD in computational and systems biology from Washington University in Saint Louis, supported by a National Science Foundation Graduate Research Fellowship. During her doctoral studies, she collaborated with St. Louis Children's Hospital to investigate the effects of early life interventions on the development of the preterm infant gut microbiome and health outcomes. Her research has resulted in multiple pending patents and publications, including articles in Science and Nature.